OMEN CDP 40MG TABLET is a combination of blood pressure-lowering medicine, and novel calcium channel blockers primarily used to treat hypertension (high blood pressure). Hypertension or high blood pressure is a chronic condition in which the blood's force against the artery wall is high. As a result, it leads to heart disease, irregular heartbeat, and other complications.
OMEN CDP 40MG TABLET contains Olmesartan medoxomil and Cilnidipine. This combination helps lower raised blood pressure effectively. Olmesartan works by blocking the hormone angiotensin, thereby relaxing blood vessels. This allows the blood to flow more smoothly and the heart to pump more efficiently. Cilnidipine blocks the activities of the calcium channels present in the blood vessels of the heart. This reduces the heart's workload and makes the heart more efficient at pumping blood throughout the body.
It would be best if you take OMEN CDP 40MG TABLET with food. It should be swallowed whole with a glass of water. Do not chew, bite, or break it. Your doctor will advise you on the dose and duration based on your medical condition. You may experience headache, nausea, peripheral oedema (swelling of legs/hands), or dizziness in some cases. Most of these side effects of OMEN CDP 40MG TABLET do not require medical attention and gradually resolve over time. However, if the side effects are persistent, reach out to your doctor.
Try not to stop taking this medicine of your own. Let your doctor know about this, as it may cause a rise in blood pressure and increase the risk of getting stroke and heart disease. OMEN CDP 40MG TABLET should be taken with caution in patients with chest pain (angina), kidney disease, heart failure, low blood pressure (hypotension), and cardiogenic shock (sudden stopping of blood flow to the heart). If you are pregnant or breastfeeding, please tell your doctor so that the dosage of OMEN CDP 40MG TABLET can be prescribed accordingly. Please inform your doctor if you are taking any other medicines or are allergic to this medicine.